# US 2014/0273211 A1 · Methods and Materials for Hematoendothelial Differentiation of Human Pluripotent Stem Cells Under Defined Conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0273211 A1
- Document ID: US20140273211A1
- Status: Published application
- Kind: A1
- Application number: 14/206,778
- Filed: 2014-03-12
- Published: 2014-09-18
- Earliest claimed: 2013-03-13
- Assignees: Wisconsin Alumni Research Foundation
- Applicants: Wisconsin Alumni Research Foundation
- Inventors: Igor I. Slukvin; Gene Ichiro Uenishi
- Web page: https://patentgrep.com/patent/US20140273211A1

## CPC

- C12N 5/0647: {Haematopoietic stem cells; Uncommitted or multipotent progenitors}
- C12N 5/0056: {Xeno-free medium}
- C12N 5/0636: {T lymphocytes}
- C12N 5/069: {Vascular Endothelial cells}
- C12N 5/0695: {Stem cells; Progenitor cells; Precursor cells}
- C12N 2500/02: Atmosphere, e.g. low oxygen conditions
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12N 2501/155: Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
- C12N 2501/16: Activin; Inhibin; Mullerian inhibiting substance
- C12N 2501/165: Vascular endothelial growth factor [VEGF]
- C12N 2502/1394: Bone marrow stromal cells; whole marrow
- C12N 2506/02: from embryonic cells
- C12N 2506/45: from artificially induced pluripotent stem cells
- C12N 2533/54: Collagen; Gelatin
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Methods and compositions for differentiating pluripotent stem cells into cells of endothelial and hematopoietic lineages are disclosed.

## Claims

### Claim 1

A method of differentiating human pluripotent stem cells, comprising the steps of:
(a) providing human pluripotent stem cells; and
(b) exposing the stem cells to a mixture comprising components FGF2, BMP4, Activin A, and LiCl under hypoxic conditions for a period of about two days to form a population of EMHlin−KDR+APLNR+PDGFRalpha+ primitive mesoderm cells with mesenchymoangioblast potential.

### Claim 2 (depends on 1)

The method of claim 1, additionally comprising the step of:
(c) exposing cells at the primitive mesoderm stage of step (b) to a mixture comprising components FGF2 and VEGF under hypoxic conditions for a period of about 1-2 days to obtain a population comprising EMHlin−KDR+APLNR+PDGFRalpha+ primitive mesoderm with hemangioblast (HB-CFC) potential and hematovascular mesoderm cells (EMHlin−KDRhiAPLNR+PDGFRalphalo/−) enriched in cells with a potential to form hematoendothelial clusters when cultured on OP9 cells.

### Claim 3 (depends on 2)

The method of claim 2, additionally comprising the step of:
(d) exposing the cells at the hematovascular mesoderm stage of step (c) to a mixture comprising components FGF2, VEGF, IL6, SCF, TPO, and IL3 for about one day to achieve formation of CD144+CD73+CD235a/CD43− non-hemogenic endothelial progenitors (non-HEP), CD144+CD73−CD235a/CD43− hemogenic endothelial progenitors (HEPs), CD144+CD73−CD235a/CD43+41a− angiogenic hematopoietic progenitors (AHP), and CD43+CD41a+ hematopoietic progenitor cells.

### Claim 4 (depends on 3)

The method of claim 3, additionally comprising the step of:
(e) continuing to expose the HEPs and emerging hematopoietic progenitor cells to a mixture comprising components FGF2, VEGF, IL6, SCF, TPO, IL3 under normoxia for about three days resulting in hematopoietic expansion to obtain a population of CD43+ hematopoietic progenitors composed of CD43+CD235a+CD41a+ erythromegakaryocytic progenitors and lin−CD34+CD43+CD45+/− multipotent hematopoietic progenitors.

### Claim 5 (depends on 1)

The method of claim 1, wherein the mixture consists essentially of the components.

### Claim 6 (depends on 5)

The method of claim 5, wherein the components are xenogen-free.

### Claim 7 (depends on 1)

The method of claim 1, wherein the cells are seeded on a substrate treated with Tenascin-C.

### Claim 8

A xenogen-free culture medium for differentiating human pluripotent stem cells, comprising IF9S medium supplemented with:
about 10 to about 50 ng/ml FGF2; and
about 20 to about 50 ng/ml VEGF.

### Claim 9 (depends on 8)

The medium of claim 8 further comprising hematopoietic cytokines.

### Claim 10 (depends on 9)

The medium of claim 9, wherein the hematopoietic cytokines comprise:
about 50 to about 100 ng/ml SCF,
about 50 to about 100 ng/ml TPO,
about 50 to about 100 ng/ml IL-6, and
about 5 to about 15 ng/ml IL-3.

### Claim 11 (depends on 8)

A concentrated form of the media of claim 8.

### Claim 12

A xenogen-free cell culture system for differentiating human pluripotent stem cells into mesoderm, endothelial, and hematopoietic progenitor cells, comprising;
human pluripotent stem cells seeded as a single cell suspension on a substrate comprising a layer of Tenascin C at a concentration of at least about 0.25 μg/cm2 to about 1 μg/cm2; and
a xenogen-free culture medium comprising IF9S medium supplemented with:
about 50 to about 250 ng/ml BMP4;
about 10 to about 15 ng/ml Activin A;
about 10 to about 50 ng/ml FGF2; and
about 1 to about 2 mM LiCl.

### Claim 13 (depends on 12)

The xenogen-free cell culture system of claim 12, wherein the xenogen-free culture medium further comprises hematopoietic cytokines.

### Claim 14 (depends on 13)

The xenogen-free cell culture system of claim 13, wherein the hematopoietic cytokines comprise:
about 50 to about 100 ng/ml SCF,
about 50 to about 100 ng/ml TPO,
about 50 to about 100 ng/ml IL-6, and
about 5 to about 15 ng/ml IL-3.

### Claim 15 (depends on 12)

The xenogen-free cell culture system of claim 12, wherein the layer of Tenascin C is at a concentration of about 0.5 μg/cm2.
